These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31345142)

  • 1. Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review.
    Fogagnolo P; Torregrossa G; Tranchina L; Ferreras A; De Cillá S; Labbé A; Figus M; Ottobelli L; Rossetti L
    Curr Med Chem; 2019; 26(22):4241-4252. PubMed ID: 31345142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment.
    Roberti G; Tanga L; Manni G; Riva I; Verticchio AC; Berardo F; Carnevale C; Oddone F
    Curr Med Chem; 2019; 26(22):4253-4261. PubMed ID: 31099319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and Molecular Tear Film Changes in Glaucoma.
    Mastropasqua R; Agnifili L; Mastropasqua L
    Curr Med Chem; 2019; 26(22):4225-4240. PubMed ID: 30306854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
    Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
    Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing Side Effects on Ocular Surface Caused by Glaucoma Eye Drops.
    Ferreras A; Figus M; Fogagnolo P; Iester M; Frezzotti P
    Curr Med Chem; 2019; 26(22):4223-4224. PubMed ID: 31612807
    [No Abstract]   [Full Text] [Related]  

  • 8. Ocular surface disease incidence in patients with open-angle glaucoma.
    Radenković M; Stanković-Babić G; Jovanović P; Djordjević-Jocić J; Trenkić-Božinović M
    Srp Arh Celok Lek; 2016; 144(7-8):376-83. PubMed ID: 29652117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Glaucoma Medication in Tear Film Osmolarity of Patients Without Symptoms of Ocular Discomfort.
    Halkiadakis I; Kontadakis GA; Tsiakou D; Patsea E; Mitropoulos P; Kandarakis AS
    J Ocul Pharmacol Ther; 2015; 31(6):330-4. PubMed ID: 26133056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors to develop ocular surface disease 
in treated glaucoma or ocular hypertension patients.
    Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
    Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glaucoma therapy and ocular surface disease: current literature and recommendations.
    Anwar Z; Wellik SR; Galor A
    Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.
    Schargus M; Ivanova S; Kakkassery V; Dick HB; Joachim S
    Cornea; 2015 Jul; 34(7):739-44. PubMed ID: 25909238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity.
    Lee SY; Wong TT; Chua J; Boo C; Soh YF; Tong L
    Eye (Lond); 2013 Oct; 27(10):1142-50. PubMed ID: 23846375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
    Potop V
    Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs.
    Yoon CH; Lee HJ; Park HY; Kim H; Kim MK; Jeoung JW; Oh JY
    Int Ophthalmol; 2020 Mar; 40(3):547-552. PubMed ID: 31705358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular surface changes in glaucoma patients related to topical medications.
    Kovačević S; Čanović S; Pavičić AD; Kolega MŠ; Bašić JK
    Coll Antropol; 2015 Mar; 39(1):47-9. PubMed ID: 26040067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye.
    Wong ABC; Wang MTM; Liu K; Prime ZJ; Danesh-Meyer HV; Craig JP
    Ocul Surf; 2018 Jul; 16(3):289-293. PubMed ID: 29510226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical glaucoma medications - Clinical implications for the ocular surface.
    Fineide F; Lagali N; Adil MY; Arita R; Kolko M; Vehof J; Utheim TP
    Ocul Surf; 2022 Oct; 26():19-49. PubMed ID: 35921942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.
    Holló G; Katsanos A; Boboridis KG; Irkec M; Konstas AGP
    Drugs; 2018 Jan; 78(1):39-64. PubMed ID: 29196953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.